TRT and Type 2 Diabetes: What the Evidence Shows

Men with type 2 diabetes sometimes also have low testosterone and wonder whether testosterone replacement therapy could improve their blood sugar. The distinction matters: treating confirmed testosterone deficiency and treating diabetes are separate clinical goals.

TRT should not be chosen primarily to lower glucose or replace diabetes treatment. Understanding the research can help you discuss a possible hormone evaluation while keeping your diabetes care on track.

Low testosterone and diabetes can coexist

The Endocrine Society's patient guide to hypogonadism  explains that testosterone deficiency is more common in men with obesity or type 2 diabetes. It also describes several possible causes, including chronic illness, medicines, and disorders involving the testes or the brain's hormone signals.

That association does not prove that raising testosterone will correct diabetes. Nor does having diabetes automatically establish a diagnosis of testosterone deficiency. Symptoms, appropriately repeated testing, and an assessment of the cause still matter.

Tell the clinician which concerns you want evaluated. A complaint such as reduced energy should be considered in the context of your overall health rather than automatically attributed to testosterone.

The guideline separates the two treatment goals

The Endocrine Society recommendation on TRT and glycemic control  recommends against testosterone therapy as a way to improve glycemic control in men with type 2 diabetes who have low testosterone.

The same guideline supports evaluating possible hypogonadism using compatible symptoms and consistently low testosterone, confirmed with repeated morning fasting measurements. A man with diabetes may still need that evaluation. The treatment decision should address the hormone deficiency, its cause, and the person's risks and goals; a hoped-for reduction in diabetes medication should not determine eligibility.

What the TRAVERSE diabetes study found

The original TRAVERSE diabetes substudy , published in 2024, compared testosterone gel with placebo in men aged 45–80 with hypogonadism and cardiovascular disease or elevated cardiovascular risk. It included 1,175 participants with prediabetes and 3,880 with diabetes.

Progression from prediabetes to diabetes did not differ significantly between groups. Testosterone also did not significantly improve glycemic remission in participants with diabetes, and changes in glucose and HbA1c were similar between groups.

These results do not support prescribing TRT as a reliable diabetes-prevention or glucose-control treatment in that population. The study tested a particular formulation in selected middle-aged and older men; it does not answer every question about every patient or establish identical outcomes in all settings.

Why another trial can produce different headlines

The original T4DM randomized trial  studied a different question. Men aged 50–74 with central obesity and impaired glucose tolerance or newly diagnosed diabetes participated in a lifestyle program. Men with pathological hypogonadism were excluded, and the study used injectable testosterone rather than gel.

After two years, fewer testosterone-treated participants met the study's diabetes criterion based on an oral glucose tolerance test. However, elevated-hematocrit safety triggers were substantially more frequent with testosterone.

Population, formulation, accompanying lifestyle care, and measured outcomes all affect interpretation. T4DM's findings should not be converted into a promise that starting routine TRT will reverse established diabetes or allow a patient to stop medication.

Symptom improvement and glucose control need separate assessment

If TRT is appropriate for a diagnosed deficiency, agree with the clinician on which symptoms or findings treatment is intended to address. Feeling better is meaningful, but it does not establish that diabetes is controlled.

Likewise, a testosterone result in the intended range does not replace reviewing the diabetes measurements your healthcare team uses. Ask how each goal will be assessed and when results will be discussed. Avoid judging the success of both treatments from one symptom, one laboratory value, or a change on the scale.

Keep your diabetes care plan in place

The NIH overview of managing type 2 diabetes  describes a plan that includes managing glucose, blood pressure, and cholesterol, taking prescribed medicines, and making appropriate lifestyle changes with the healthcare team.

Discuss food, activity, weight management, and other care needs with the clinician managing your diabetes. Testosterone research does not remove those needs. Continue the monitoring and treatment instructions you have been given unless your clinician changes them.

If you are considering TRT, make sure the testosterone clinician knows your diabetes history and that your diabetes clinician knows about the proposed treatment. Care is easier to coordinate when both have the current medication list and relevant results.

Review possible medication effects with your clinicians

No average glucose benefit in a trial does not mean that an individual can ignore glucose changes. The testosterone cypionate label's diabetes interaction information  states that androgens may decrease blood glucose and therefore insulin requirements in people with diabetes.

If you use insulin, tell both clinicians before starting or changing testosterone treatment. Ask how glucose concerns should be reported and who will review them. Do not reduce insulin or other diabetes medicine on your own because you started TRT, feel better, or read about a study.

Bring focused questions to a hormone consultation

Ask what evidence supports a diagnosis of testosterone deficiency, whether a potentially reversible contributor needs attention, and what benefit treatment would reasonably aim to provide. Discuss the risks, alternatives, and follow-up requirements.

Also clarify who manages diabetes medicines and reviews glucose results. Bring complete dated reports and an up-to-date medication list so the discussion reflects your current care rather than an isolated testosterone number.

Frequently asked questions

Can TRT replace my type 2 diabetes medicine?

No. TRT should not be used as a substitute for diabetes treatment. Medication changes belong with the clinician managing your diabetes, based on your individual assessment.

Does type 2 diabetes mean I can never receive TRT?

No. Possible testosterone deficiency can be evaluated on its own merits. A diagnosis, the cause, treatment goals, and individual risks determine whether therapy is appropriate.

Can TRT reliably prevent prediabetes from becoming diabetes?

That is not a supported promise. TRAVERSE did not find a significant prevention benefit, and results from a different trial population should not be treated as a guarantee for you.

Could glucose change even if TRT is not a diabetes treatment?

Yes, individual changes are possible. Product labeling describes potential effects on glucose and insulin requirements. Discuss monitoring with your clinicians and follow their instructions rather than changing medicines yourself.

Discuss testosterone concerns through California telehealth

Men in Los Angeles and elsewhere in California can explore SoCal Testosterone Clinic's testosterone replacement service  and contact the practice about a California TRT consultation . California-only telehealth is available now, with no in-person clinic appointments. Ask about evaluating hormone concerns while continuing appropriate diabetes care with your healthcare team.